Aneuploidy may be used as a more sensitive diagnostic tool to detect peritoneal metastasis compared to conventional cytology and imaging techniques. Our aim is to establish whether aneuploidy as detected in cfDNA (as a measure for ctDNA) in PLF of patients with GC may hold value as an additional staging and tumor evaluation method in GC patients.
Age ≥18 years old;
Written informed consent according to the ICH-GCP and national/local regula-tions.
Operable patients who will undergo a planned diagnostic laparoscopy for a benign indication bariatric or gallbladder disease);
Age ≥18 years old;
Written informed consent according to the ICH-GCP and national/local regulations.
Active inflammation or infection;
Gastric cancer patients: Patients who will undergo DLS for GC or GEJ carcinoma Non-cancer controls: Operable patients who will undergo a planned diagnostic laparoscopy for a benign indication (bariatric or gallbladder disease);
Cohort
Prospective
collection additional peritoneal lavage fluid
Other interventioncollection additional peritoneal lavage fluid
Sensitivity mFast-SeqS
The primary endpoint is the sensitivity of the mFast-SeqS technique in patients with GC, and refers to the ability of the mFast-SeqS technique to correctly identify patients with the pres-ence of tumor cells in the peritoneal cavity.
DFS
No locoregional or distant recurrence of disease,
Concordance detection rates peritoneal dissemination
• Concordance of detection rates of peritoneal dissemination will be analyzed using cohen's kappa/mcNemar's test
Click on the lead sponsor to view all of their trials.
